R&D channel feed – Endpoints News

R&D channel feed

Valneva's chikungunya vaccine on track for FDA nod after long-term antibody data

3 years ago

Amgen, years behind rivals, says PhI obesity drug shows durability signs

3 years ago

Salarius Pharmaceuticals sees withdrawals, 3 of 13 patient responders in sarcoma trial

3 years ago

FDA rejects Y-mAbs’ neuroblastoma drug after taking issue with clinical trial design

3 years ago

Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment

3 years ago

Pfizer and Roivant team up again for another 'Vant', setting up anti-inflammatory showdown with Prometheus

3 years ago

As competitors near FDA goalpost, Roche spells out its repeat Alzheimer's setback

3 years ago

As money pours into digital therapeutics, insurance coverage crawls

3 years ago

SQZ Biotech slashes headcount by 60% as founder/CEO hits exit — while Synlogic lays off 25%

3 years ago

Rallybio, AbCellera form new partnership around antibodies for rare disease

3 years ago

Eli Lilly’s Alzheimer’s drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter?

3 years ago

Sanofi and DNDi aim to eliminate sleeping sickness in Africa with promising Ph II/III results for new drug

3 years ago

Protecting its megablockbuster, Janssen challenges Amgen's Stelara biosimilar ahead of planned 2023 launch

3 years ago

In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline

3 years ago

X4 Pharmaceuticals pulls together some positive data results after a rocky year

3 years ago

Jim Wilson biotech iECURE gets fresh $65M to push pediatric liver disease gene therapy into the clinic

3 years ago

PhIIb win puts Nimbus one step closer to challenging Bristol Myers in TYK2

3 years ago

Eisai’s expanded Alzheimer’s data leave open questions about safety and clinical benefit

3 years ago

Allogene takes the stage in New York to go deep on its off-the-shelf cell therapies — declaring a first for solid tumors

3 years ago

Ikena Oncology drops an early-stage program as it looks to stretch its cash

3 years ago

Mirum discontinues PhIIb 'Ohana' study in pregnancy setting

3 years ago

New TIGIT data cut from Gilead, Arcus sets the stage for full readout

3 years ago

Fourth accelerated approval in Duchenne? Sarepta gets priority review for gene therapy amid FDA scrutiny

3 years ago

CinCor’s hypertension candidate flops a PhII test but plans to charge ahead with pivotal study

3 years ago

First page Previous page 110 111 112113114 115 116 Next page Last page